Keppra is a trade name for levetiracetam, an anti-seizure medicine used to treat epilepsy, including partial-onset, myoclonic, and tonic-clonic seizures. It acts as an SV2A ligand and is available in oral and intravenous forms. Levetiracetam was approved for medical use in the United States in 1999.
Northwestern University researchers found that levetiracetam, an FDA-approved anti-seizure medication, prevents formation of toxic amyloid-beta 42 peptides in the brain, offering a potential strategy for early Alzheimer's prevention.
The FDA has authorized the first human trial of an allogeneic stem cell therapy for epilepsy, developed by Shanghai-based Unixell Biotechnology. The therapy uses donor-derived stem cells to produce GABA and suppress seizures in drug-resistant patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00859521 |
Levetiracetam 1000 mg Under Fasting Conditions |
COMPLETED | PHASE1 |
| NCT00859430 |
Levetiracetam 1000 mg Under Non-Fasting Conditions |
COMPLETED | PHASE1 |
| NCT00849862 |
Levetiracetam 750 mg Tablets Under Fasting Conditions |
COMPLETED | PHASE1 |
| NCT00849485 |
Levetiracetam 750 mg Tablets Under Non-Fasting Conditions |
COMPLETED | PHASE1 |
